Clinical Cancer Investigation Journal

ORIGINAL ARTICLE
Year
: 2020  |  Volume : 9  |  Issue : 1  |  Page : 1--6

Comparison of survival between hodgkin and non-hodgkin lymphoma after autologous stem cell transplantation


Abbas Hajifathali1, Mahshid Mehdizadeh2, Tina Vosoughi3, Mahdi Tabarraee4, Afshin Talebi5, Seyed Mohammad Sadegh Pezeshki6, Najmaldin Saki3, Saeed Hesam7, Molook Salemzadeh8 
1 Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Bone Marrow Transplantation Ward, (Ayatollah) Taleghani Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
4 Department of Hematology and Medical Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5 Department of Internal Medicine, School of Medicine, Razi Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
6 Thalassemia and Hemoglobinopathy Research Center, Health Research Institute; Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
7 Department of Biostatistics, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Khouzestan, Iran
8 Golestan Hospital Clinical Research Development Unit, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Correspondence Address:
Tina Vosoughi
Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz
Iran

Background: Autologous stem cell transplantation (ASCT) is a treatment modality for non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) patients with increasingly usage worldwide. Materials and Methods: One hundred and forty-one patients (96 patients with HL and 45 patients with NHL) who underwent ASCT were followed. We used 3-year overall survival (OS) and 3-year progression-free survival (PFS) to evaluate the survival rates. Results: Comparison of 3-year OS and PFS between HL and NHL had no statistically significant difference (OS: 82% vs. 70.2%,P = 0.07 and PFS: 72.8% vs. 59.6%,P = 0.46). 3-year OS in HL with CR was, however, statistically better than NHL (91% vs. 70.4%,P = 0.007) and 3-year OS in males with HL was statistically better than males with NHL (83.2% vs. 66.7%,P = 0.047). Moreover, 3-year OS and PFS in HL with three or more chemotherapy lines before transplantation were better than NHL with this condition (3-year OS: 72.8% vs. 44%,P = 0.01 and 3-year PFS: 58.1% vs. 33.1%,P = 0.016). Conclusion: Our purpose was to compare the survival rates in two groups of NHL and HL patients after ASCT. Patients with HL generally showed better OS and PFS after ASCT in comparison to patients with NHL, but statistically significant differences were seen only in few comparisons, requiring more studies to be carried out.


How to cite this article:
Hajifathali A, Mehdizadeh M, Vosoughi T, Tabarraee M, Talebi A, Sadegh Pezeshki SM, Saki N, Hesam S, Salemzadeh M. Comparison of survival between hodgkin and non-hodgkin lymphoma after autologous stem cell transplantation.Clin Cancer Investig J 2020;9:1-6


How to cite this URL:
Hajifathali A, Mehdizadeh M, Vosoughi T, Tabarraee M, Talebi A, Sadegh Pezeshki SM, Saki N, Hesam S, Salemzadeh M. Comparison of survival between hodgkin and non-hodgkin lymphoma after autologous stem cell transplantation. Clin Cancer Investig J [serial online] 2020 [cited 2020 May 26 ];9:1-6
Available from: http://www.ccij-online.org/article.asp?issn=2278-0513;year=2020;volume=9;issue=1;spage=1;epage=6;aulast=Hajifathali;type=0